GSK wins early FDA accelerated approval for lung cancer drug Nelkarmi
RTTNews · · AI-summarised by FinFlash
The US FDA granted accelerated approval to GSK's Nelkarmi (neladalkib) for adults with advanced ALK-positive non-small cell lung cancer that progressed after prior therapy, ahead of a November 27 target date. In the ALKOVE-1 trial, the response rate was 49% in patients previously treated only with alectinib and 32% in more heavily pretreated patients. GSK's US-listed shares closed Tuesday down 2.32% at $49.24.
So What?
The approval strengthens GSK's oncology pipeline from its Nuvalent deal and adds competition in the ALK lung cancer market; watch GSK shares in London trade.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.